Expertise in
14
conditions

Dr. Daniel P. Petrylak

Oncology
Yale University School Of Medicine
333 Cedar St, 
New Haven, CT 
Offers Telehealth
Expertise in
14
conditions
Yale University School Of Medicine
333 Cedar St, 
New Haven, CT 

Overview

Daniel Petrylak is an Oncologist practicing medicine in New Haven, Connecticut.

Dr. Petrylak is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Urothelial Cancer, Familial Prostate Cancer, Orchiectomy, and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 197 peer reviewed articles and participating in 15 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

Yale-New Haven Hospital
Bridgeport Hospital
Lawrence & Memorial Hospital
Greenwich Hospital Association -

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Yale University School of Medicine
333 Cedar St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2026
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: June 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Docetaxel
Study Phase: Phase 3
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Enrollment Status: Suspended
Publish Date: October 06, 2022
View 9 Less Clinical Trials

197 Total Publications

Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.
Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: April 24, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Smilow Cancer Hospital

35 Park St, 
New Haven, CT 
 (0.2 miles away)
203-200-5864
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Gettinger is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Gettinger is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-785-7385
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elena Ratner is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Ratner is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Salpingo-Oophorectomy, and Vaginectomy.

Expertise in
22
conditions
Dr. Harriet Kluger
Hematology | Oncology
Expertise in
22
conditions
Dr. Harriet Kluger
Hematology | Oncology
Referral may be required

Smilow Cancer Hospital

35 Park St, # Np8, 
New Haven, CT 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Harriet Kluger is a Hematologist and an Oncologist practicing medicine in New Haven, Connecticut. Dr. Kluger is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma (RCC), Metastatic Brain Tumor, and Nephrectomy.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-200-5864
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anne Chiang is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Chiang is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Yale University School Of Medicine

333 Cedar St, 
New Haven, CT 
 (0.1 miles away)
203-785-7564
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sarah Goldberg is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Goldberg is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-200-2328
Languages Spoken:
English
See accepted insurances

Lajos Pusztai is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Pusztai is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Triple-Negative Breast Cancer, Breast Cancer, Inflammatory Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Tissue Biopsy.

Frequently Asked Questions about Dr. Daniel P. Petrylak

How do I make an appointment with Dr. Daniel P. Petrylak?

You can book an appointment with Dr. Daniel P. Petrylak by calling their office at 203-785-3597. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel P. Petrylak a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel P. Petrylak is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel P. Petrylak specialize in?

While Dr. Daniel P. Petrylak is a Oncology, they have specific expertise in Prostate Cancer, Urothelial Cancer, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Daniel P. Petrylak participate in research or clinical trials?

Yes. Dr. Daniel P. Petrylak has published 197 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Daniel P. Petrylak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel P. Petrylak accept my insurance?

Dr. Daniel P. Petrylak accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 203-785-3597 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Petrylak's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile